Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Raw Materials (2023 - 2024)

Historic Raw Materials for Seres Therapeutics (MCRB) over the last 2 years, with Q2 2024 value amounting to $4.9 million.

  • Seres Therapeutics' Raw Materials rose 80201.1% to $4.9 million in Q2 2024 from the same period last year, while for Jun 2024 it was $4.9 million, marking a year-over-year increase of 80201.1%. This contributed to the annual value of $4.4 million for FY2023, which is N/A changed from last year.
  • As of Q2 2024, Seres Therapeutics' Raw Materials stood at $4.9 million, which was up 80201.1% from $4.2 million recorded in Q1 2024.
  • Seres Therapeutics' Raw Materials' 5-year high stood at $4.9 million during Q2 2024, with a 5-year trough of $547000.0 in Q2 2023.